BioPorto A/S

Copenhagen Stock Exchange BIOPOR.CO

BioPorto A/S Total Non-Current Liabilities for the year ending December 31, 2023: USD 633.53 K

BioPorto A/S Total Non-Current Liabilities is USD 633.53 K for the year ending December 31, 2023, a -40.72% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

BioPorto A/S Total Non-Current Liabilities for the year ending December 31, 2022 was USD 1.07 M, a -33.41% change year over year.
BioPorto A/S Total Non-Current Liabilities for the year ending December 31, 2021 was USD 1.60 M, a 16.04% change year over year.
BioPorto A/S Total Non-Current Liabilities for the year ending December 31, 2020 was USD 1.38 M, a 269.28% change year over year.
BioPorto A/S Total Non-Current Liabilities for the year ending December 31, 2019 was USD 374.55 K, a 209.84% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

Copenhagen Stock Exchange: BIOPOR.CO

BioPorto A/S

CEO	Mr. Peter Moerch Eriksen B.B.A., BBA
IPO Date	Jan. 13, 2000
Location	Denmark
Headquarters	Tuborg Havnevej 15, st.
Employees	27
Sector	Health Care
Industries Biotechnology Medical Instruments Pharmaceuticals

Description

BioPorto A/S, an in-vitro diagnostics company, provides biomarker tests and tools, and antibodies for clinicians and researchers in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. The company was incorporated in 1917 and is based in Hellerup, Denmark.

Key trends

Past 5 years